AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- Novavax, Inc. was working on its plan to introduce a single injection that protects against Covid-19 and seasonal flu.
- Novavax informed that it expects to launch the combo vaccine later this year.
Many scientists have predicted that the Covid-19 booster dose will be required each year; therefore, pharmaceuticals companies are working on combing seasonal flu, and Covid-19 does. Clinical stage company, Novavax, Inc. (NYSE:NVAX) was already working its plan to introduce a single injection that protects against Covid-19 and seasonal flu. Novavax shared an update that it expects to launch a new trial of the combo vaccine later this year.
Must read: Australian kids aged 6-11 can now get Moderna’s COVID-19 vaccine
In the earnings call on Tuesday, Stanley Erck, CEO of Novavax, informed that it has brought its vaccine to the market. He also announced that the company had gained authorisation in 38 countries.
Novavax work on the Covid-flu combo
Since the beginning of the pandemic, Novavax has been working on developing the Covid-flu combo vaccine. Researchers at China’s Northwest A&F University said the study that was published in the journal PLOS Biology that,
The company reported success only a few months back as it received provisional approvals in the EU, Canada, the UK and Australia.
In September 2021, to assess the combined vaccine's immune response, tolerability and safety, the company enrolled people in a phase 1/2 study. Protein subunit technology is used in these vaccines and generated positive results as standalone vaccines during the phase 3 trial.
Phase 1/2 final data can be expected in the coming months. Later this year, Novavax is also planning to launch phase 2 trials. Initial data would guide the new trials to decide the dosing profile, said Erck. He added that
Has Australia ordered the Novavax vaccine?
Image source: © Syhinstas | Megapixl.com
Australia has ordered 51 million doses. The vaccine is available for those who have not received the first and second dose yet. Novavax management informed that 6 million doses landed in Australia in the past couple of months during the call.
Suggested reading: Novavax vaccine now available in Australia - here's how to get it
Novavax shared revenue guidance for the first time
With the international sales of its first commercial product, Novavax is sharing the revenue guidance for the first time. In 2022, the company expects revenue in the range of US$4 million to US$5 million, driven by bulk orders.
Moreover, the Novavax vaccine is a protein vaccine and, therefore can be stored at normal refrigerator temperature.
